Notable disparities were observed between the two groups regarding improvements of BMI, SBP, HbA1c, LDL-C, CRP
Haver integrates a patients medical history, symptomatology, nutrition, exercise, supplements, and possibly hormone therapy, or what she likes to call The Menopause Toolkit. Dr
Primary outcomes Compared to SGLT2i monotherapy, combination therapy with SGLT2i and GLP-1RA was associated with a lower risk of the primary composite outcome (HR, 0.87
Importantly, fracture rates in GLP-1 treatment groups were comparable to placebo groups, suggesting that skeletal risk does not significantly exceed that of equivalent weight loss achieved through other means
Tirzepatide: Also administered via injection
You may have medications that should be changed if they are interfering with your attempts to lose weight